Boiron SA

Boiron SA

BOI · PA · Healthcare / Drug Manufacturers - Specialty & Generic

19.20EUR+0.15 (+0.79%)

Price History

Full chart

Market Stats

Previous Close19.05
Open19.25
Day Range18.95 – 19.25
52-Week Range19.30 – 30.73
Volume1.71K
Market Cap343.77M
P/E (TTM)13.11
Forward P/E15.55
EPS1.51
Dividend Yield6.80%
Beta0.21
50-Day Avg25.11
200-Day Avg27.19

About

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers homeopathic medicines and homeopathic specialties; and other healthcare products, including medical devices (in vitro diagnostics), dietary supplements, herbal remedies, cosmetics, and CBD-based products. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; Sedative PC Granules to treat anxiety and emotional, and minor sleep disorders; Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; Homéovox for vocal disorders; Homéoplasmine for treating irritated skin and redness; Varésol to treat symptoms of chickenpox; and Arnicare Arthritis for use in the treatment of benign trauma pain. In addition, it offers Dermoplasmine, a plant based multi-use balm that repairs and protects irritated and damaged skin; COVID self-tests and rapid antigenic tests; LABIAMEO, that used to treat outbreaks of localized cold sores; and CONVAMEO to treat physical and mental asthenia. Further, the company provides Quietude, Rhinallergy, Ribes Nigrum Macerate Glycerin 1 DH Boiron, Sabal serrulata Mother Tincture Boiron, Sevameo, Sinupyl, Sportenine, Stodaline Sugar-Free, Stodal Granules, Stodal Syrup, Storinyl, Sedative PC Sublingual Tablet, Tilia Tomentosa Glycerinated Macerate 1DH Boiron, Varesol, Verrulia, Avenoc Suppository, Calendula Cream, Zelaceo, and Zenalia. It offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is based in Messimy, France.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Thierry Boiron
  • Employees2.62K
  • Headquarters2, avenue de l?Ouest Lyonnais, Messimy, France, 69510, France
  • Websitehttps://www.boiron.fr

Leadership

  • Mr. Thierry BoironDeputy GM & Director · b. 1961
  • Mr. Fabrice ReyGroup Treasurer
  • Mr. Pascal HoudayerGM & Director · b. 1969
  • Mr. Patrice VarrautDirector of Operations
  • Julien NavarraLegal Director
  • Gregoire BalayMarketing Director
  • Ms. Juliette BaudryHuman Resources Director
  • Mr. Eric LambertSecretary General

Financials

Income Statement

Currency: EUR2001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue266.39M287.05M305.34M290.63M361.65M398.67M434.47M466.89M526.28M520.60M523.45M566.29M617.99M609.98M607.96M614.49M617.54M604.22M557.12M513.58M455.20M534.24M493.25M487.56M501.11M
Growth (%)-+7.76%+6.37%-4.82%+24.43%+10.24%+8.98%+7.46%+12.72%-1.08%+0.55%+8.18%+9.13%-1.30%-0.33%+1.07%+0.50%-2.16%-7.79%-7.82%-11.37%+17.36%-7.67%-1.15%+2.78%
Cost of Revenue27.13M27.43M30.79M60.57M81.04M88.42M90.34M99.61M114.07M111.28M118.60M126.87M124.77M117.56M118.98M125.15M128.15M134.65M127.22M118.84M127.58M154.51M135.16M128.80M135.38M
Gross Profit239.26M259.62M274.55M230.07M280.60M310.25M344.13M367.29M412.21M409.32M404.86M439.43M493.22M492.42M488.98M489.35M489.39M469.57M429.90M394.74M327.62M379.73M358.08M358.76M365.73M
Gross Margin89.82%90.44%89.92%79.16%77.59%77.82%79.21%78.67%78.33%78.63%77.34%77.60%79.81%80.73%80.43%79.63%79.25%77.72%77.16%76.86%71.97%71.08%72.60%73.58%72.98%
Operating Expense207.90M222.78M235.03M196.84M255.96M290.98M299.44M310.10M320.44M342.67M341.16M358.32M347.19M346.31M353.80M355.43M359.38M361.17M357.71M356.56M290.19M323.90M315.79M343.03M330.32M
Operating Income31.36M36.84M39.52M33.22M24.65M19.28M44.69M57.19M91.77M66.65M63.70M81.11M146.03M146.11M135.18M133.92M130.01M108.40M72.19M38.19M37.43M55.83M42.29M15.74M35.40M
Operating Margin11.77%12.83%12.94%11.43%6.82%4.84%10.29%12.25%17.44%12.80%12.17%14.32%23.63%23.95%22.23%21.79%21.05%17.94%12.96%7.44%8.22%10.45%8.57%3.23%7.06%
EBITDA42.94M51.48M56.69M48.46M49.01M38.00M63.04M81.51M110.88M87.58M86.57M117.17M156.40M167.74M150.91M157.00M159.38M138.56M99.16M68.91M78.75M91.33M73.67M45.46M66.30M
EBITDA Margin16.12%17.93%18.57%16.67%13.55%9.53%14.51%17.46%21.07%16.82%16.54%20.69%25.31%27.50%24.82%25.55%25.81%22.93%17.80%13.42%17.30%17.10%14.94%9.32%13.23%
Net Income19.70M23.02M25.63M20.59M16.41M10.24M27.16M39.18M59.89M43.28M42.26M49.63M82.40M89.05M73.93M77.72M78.24M57.46M40.63M26.21M28.56M44.67M35.83M11.34M32.64M
Net Income Margin7.39%8.02%8.39%7.09%4.54%2.57%6.25%8.39%11.38%8.31%8.07%8.76%13.33%14.60%12.16%12.65%12.67%9.51%7.29%5.10%6.27%8.36%7.26%2.33%6.51%
R&D---3.43M4.97M6.07M5.71M6.57M4.28M6.34M4.56M6.64M6.28M5.40M4.21M3.95M3.59M3.83M3.13M3.52M2.99M6.09M5.76M6.31M5.66M
R&D as % of Total Revenue---1.18%1.38%1.52%1.31%1.41%0.81%1.22%0.87%1.17%1.02%0.89%0.69%0.64%0.58%0.63%0.56%0.68%0.66%1.14%1.17%1.29%1.13%
Interest Expense1.10M00225.00K927.00K995.00K693.00K367.00K613.00K190.00K229.00K669.00K634.00K1.22M1.20M1.13M724.00K207.00K420.00K348.00K537.00K1.54M1.19M1.61M1.70M
Interest Expense % of Total Revenue0.41%0.00%0.00%0.08%0.26%0.25%0.16%0.08%0.12%0.04%0.04%0.12%0.10%0.20%0.20%0.18%0.12%0.03%0.08%0.07%0.12%0.29%0.24%0.33%0.34%

Balance Sheet

Currency: EUR2001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets205.86M230.73M247.97M271.02M427.25M412.06M428.39M463.34M521.93M558.34M587.61M579.28M667.59M669.55M695.45M755.03M800.40M767.08M764.28M781.82M770.70M789.49M590.20M576.33M602.81M
Total Liabilities86.69M96.26M98.44M126.93M197.37M181.97M178.45M191.86M208.66M214.50M218.96M225.12M275.73M289.67M279.40M285.44M282.91M281.03M258.82M272.65M238.93M232.15M198.70M198.15M210.03M
Total Equity119.08M134.37M149.42M143.97M229.67M229.91M249.60M271.14M313.06M343.62M368.43M353.96M391.70M379.73M415.95M469.52M517.46M486.00M505.48M509.14M531.74M557.62M393.66M378.14M392.76M
Cash19.52M5.21M9.52M40.67M26.95M35.94M55.00M75.75M99.76M102.10M91.65M96.52M160.95M161.03M195.41M244.31M275.01M217.25M208.44M234.69M234.50M250.94M74.04M64.71M79.34M
Total Debt4.57M4.79M5.47M4.49M27.55M22.63M9.08M3.69M5.66M7.04M5.17M5.75M5.30M9.86M8.79M9.25M15.97M5.99M13.02M12.43M12.61M22.17M13.70M14.97M31.48M
Net Debt-14.95M-413.00K-4.05M-36.18M606.00K-13.31M-45.92M-72.06M-94.10M-95.06M-86.48M-90.77M-155.65M-151.18M-186.62M-235.05M-259.03M-211.26M-195.43M-222.25M-221.90M-228.78M-60.34M-49.74M-47.85M

Cash Flow

Currency: EUR2001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow33.27M34.46M36.73M34.40M41.74M38.57M56.13M65.48M80.20M51.64M58.82M88.59M107.02M96.16M103.16M110.13M104.75M84.25M50.86M68.27M33.32M58.69M45.49M39.53M53.24M
Investing Cash Flow-18.52M-15.28M-3.23M-22.27M-47.59M-16.29M-18.25M-24.10M-41.63M-37.31M-53.17M-19.14M-24.24M-22.07M-26.45M-34.22M-51.18M-39.41M-33.56M-19.34M-11.92M-15.28M-22.93M-18.36M-23.39M
Financing Cash Flow-9.36M-7.36M-9.89M-10.09M-11.08M-10.46M-21.72M-16.57M-16.97M-14.10M-13.65M-64.81M-17.12M-77.13M-44.63M-27.36M-29.25M-91.96M-27.19M-21.52M-22.00M-27.58M-198.41M-27.85M-24.39M
Capital Expenditure19.19M16.16M33.36M22.88M9.96M20.58M20.11M28.27M44.12M41.93M53.25M20.74M17.00M16.00M16.90M27.81M45.27M40.88M37.53M20.70M20.42M18.59M18.02M8.40M23.52M
Free Cash Flow14.08M18.30M3.37M11.52M31.78M17.99M36.02M37.21M36.08M9.71M5.57M67.85M90.02M80.15M86.26M82.33M59.48M43.37M13.33M47.57M12.90M40.10M27.47M33.77M29.72M
Dividends Paid7.24M7.46M8.63M9.67M9.69M8.10M6.58M11.95M12.89M15.02M15.04M15.03M17.48M23.33M27.66M27.65M29.48M28.30M25.39M18.38M16.64M16.50M198.97M23.44M20.84M
FCF to OCF42.32%53.09%9.17%33.49%76.13%46.63%64.16%56.83%44.99%18.80%9.46%76.59%84.11%83.36%83.62%74.75%56.78%51.47%26.21%69.68%38.72%68.32%60.38%85.42%55.82%
Dividend Paid to FCF51.38%40.77%256.29%83.94%30.49%45.01%18.28%32.11%35.71%154.73%270.07%22.15%19.42%29.10%32.06%33.58%49.57%65.27%190.45%38.64%129.03%41.15%724.42%69.41%70.11%

Earnings

Report DateMar 19, 2014Aug 29, 2014Mar 18, 2015Sep 3, 2015Mar 16, 2016Sep 8, 2016Oct 20, 2016Mar 15, 2017Apr 20, 2017Sep 7, 2017Oct 19, 2017Mar 14, 2018Apr 26, 2018Sep 5, 2018Oct 18, 2018Mar 13, 2019Apr 26, 2019Sep 4, 2019Oct 24, 2019Mar 11, 2020Apr 23, 2020Sep 9, 2020Dec 2, 2020Mar 10, 2021Apr 22, 2021Sep 8, 2021Oct 21, 2021Mar 9, 2022Apr 26, 2022Sep 7, 2022Oct 20, 2022Jan 19, 2023Apr 27, 2023Jul 18, 2023Oct 20, 2023Mar 13, 2024Apr 23, 2024Sep 4, 2024Nov 27, 2024Mar 12, 2025Apr 22, 2025Sep 18, 2025Dec 3, 2025Mar 18, 2026
EPS Estimate0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00-0.000.000.000.000.000.000.000.000.000.000.000.000.000.00
EPS Actual0.000.000.000.000.000.000.000.000.001.350.002.900.001.200.002.050.00-0.020.002.340.00-0.060.001.550.00-0.540.002.170.000.720.001.850.000.000.000.000.000.000.000.460.460.650.000.00
Surprise--------------------------------------------
Timing-----------------------------After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours---------

Key Statistics & Ratios

Market Cap343.77M
Enterprise Value316.90M
Trailing P/E13.11
Forward P/E15.55
PEG Ratio2.38
Price / Sales0.69
Price / Book0.92
EPS1.51
Book Value21.62
Revenue (TTM)495.78M
Gross Profit (TTM)357.94M
EBITDA56.70M
Profit Margin5.28%
Operating Margin3.96%
Return on Equity7.04%
Return on Assets4.33%
Shares Outstanding17.36M
Shares Float3.50M
Beta0.21
Dividend Yield6.80%
Dividend Rate1.35
Payout Ratio89.40%

Dividends

20261×
1.35Jun 3, 2026
20251×
1.20Jun 3, 2025
20241×
1.35Jun 3, 2024
20232×
10.36Oct 18, 20231.10Jun 1, 2023
20221×
0.95Jun 1, 2022
20211×
0.95Jun 2, 2021
20201×
1.05Jun 2, 2020
20191×
1.45May 30, 2019
20181×
1.60May 31, 2018
20171×
1.60May 31, 2017
20161×
1.50Jun 1, 2016
20151×
1.50Jun 3, 2015
20141×
1.20Jun 3, 2014
20131×
0.90May 31, 2013
20121×
0.70May 30, 2012
20111×
0.70May 31, 2011
20101×
0.70Jun 1, 2010
20091×
0.60Jun 2, 2009
20081×
0.55Jun 2, 2008
20071×
0.30Jun 6, 2007
20061×
0.37Jun 5, 2006
20051×
0.52Jul 4, 2005
20041×
0.52Jun 14, 2004

Stock Splits

  • Jul 1, 20034:1
  • Jul 2, 19972:1
  • Jul 4, 19945:4